M Ventures has returned to back the cancer therapeutics developer’s $75.5m round, five years after taking part in its series A.

Germany-based oncology therapy developer iOmx Therapeutics received €65m ($75.5m) in series B funding on Tuesday from investors including M Ventures, a corporate venturing arm of pharmaceutical firm Merck Group.

The Strüngmann family office, Athos Service, co-led the round with investment management firm MIG Capital and it included Sofinnova Partners and Wellington Partners.

Founded in 2016, iOmx is developing immunotherapy drugs that target cancer tumour-associated immune-checkpoint molecules through the company’s target discovery platform, iOTarg.

M Ventures – then known as Merck…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn